Aramchol ( DrugBank: Aramchol )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 1 |
265. Lipodystrophy
Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02684591 (ClinicalTrials.gov) | January 2016 | 15/1/2016 | Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy | Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial | Nonalcoholic Fatty Liver Disease;HIV | Drug: Aramchol;Drug: Placebo | University of California, San Diego | NULL | Completed | 18 Years | N/A | All | 50 | Phase 2 | United States |